The mechanism of viral gene silencing during HSV latency is not understood. While transcription of the viral IE genes is silenced, an RNA referred to as latency associated transcript (LAT) is transcribed. LAT is considered a stable intron. Viral protein associated with the LAT transcription unit has not been identified. This application describes the use of HSV mutants to investigate HSV gene expression during latency. Mutant viruses with as many as three IE genes have been deleted. These IE genes are ICPO, 4, 22, and 27.
The specific aims of this proposal are as follows: (i) To determine the genetic basis of IE gene promoter silencing and its role in the establishment of latency. (ii) To characterize cis-acting elements associated with the ICPO promoter during latency or reactivation. (iii) To determine the role of the LAT intron in silencing ICPO expression (iv) To characterize cis-acting elements associated with two LAT promoters designated LAP1 and LAP2. (v) To determine the role of chromatin and DNA methylation in promoter silencing during latency. During infection of neurons with IE triple mutants of HSV, the viral ICPO promoter remains active for 2 to 4 weeks in contrast to wild type HSV. Since ICP4 deleted mutants still silence ICPO transcription, the applicant proposes that the ICP27 and ICP22 viral gene products have a role in silencing ICPO promoter activity. To further investigate these observations, promoter switching experiments whereby the ICPO promoter is substituted by either the ICP4, 27, or 47 promoters is proposed. The mutant viruses will be inoculated into the hippocampus of rat brain and the activity of the promoters relative to the number of viral genome equivalents will be determined by RT-PCR. Mutant viruses with the ICPO gene substituted by a reported gene (lacZ) will be analyzed to determine if the ICPO gene product autoregulates its own promoter. The effects of the level of ICP4, 27, and 22 gene expression on ICPO gene expression will be determined by using a regulation system for gene expression consisting of a Gal4 DNA binding domain-VP16-RU486 fusion described by the O'Malley lab that is induced by the hormone progesterone. In the second specific aim, the cis-acting elements in the ICPO promoter that are required for escape from silencing and reactivation from latency will be investigated. Site-directed mutagenesis of potential cis-acting elements and repeat sequences, 5' and 3' truncations and internal deletions will be used to analyze the promoter. The putative cis-acting elements in the ICPO intron will also be analyzed. Latency will be established by the corneal scarification method using mice and the number of latent genomes in the trigeminal ganglia will be determined by quantitative PCR. The applicant proposes that the transcription factor E2F may have a role in ICPO promoter activity. In the third specific aim, the role of the LAT RNA in regulating the level of ICPO RNA will be analyzed. Since the two viral RNAs have complementary sequences, the LAT RNA may target the ICPO RNA for degradation. Mutant viruses that fail to express the 2 kb LAT RNA may fail to downregulate ICPO RNA levels whereas over expression of the 2 kb LAT RNA may efficiently downregulate. To extend this line of research, the applicant proposes to use a yeast system with selectable markers and reporter genes. The yeast system could be used to determine the regions of the LAT RNA required for hybridization to ICPO RNA and, subsequent destruction of ICPO RNA. In the fourth specific aim, the functional elements of the two latency active promoters, LAP1 and LAP2, will be subjected to site-directed mutagenesis. Both common cis-acting sites and brain specific cis-acting sites will be mutagenized. An interesting approach will be to use transcription factor Brn knock-out mice to determine the effects of the brain specific transcription factors and cis-acting elements. In the fifth specific aim, the viral chromatin and the methylation state of the viral DNA will be analyzed with an emphasis on the ICPO and LAP regions. Chromatin arrangement and/or DNA methylation may have a role in silencing IE gene transcription. The differences in the chromatin profile or methylation profiles between wild type virus and IE deletion virus will be determined. Differences in nucleosome arrangement will be analyzed by a nuclease sensitivity assay. Differences in the CpG sequence methylation will be analyzed.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM034534-18
Application #
6018632
Study Section
Virology Study Section (VR)
Program Officer
Kerza-Kwiatecki, a P
Project Start
1989-09-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
18
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Genetics
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Tsvitov, Marianna; Frampton Jr, Arthur R; Shah, Waris A et al. (2007) Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360:477-91
Jiang, Canping; Glorioso, Joseph C; Ataai, Mohammad (2006) Presence of imidazole in loading buffer prevents formation of free radical in immobilized metal affinity chromatography and dramatically improves the recovery of herpes simplex virus type 1 gene therapy vectors. J Chromatogr A 1121:40-5
Hong, C-S; Goins, W F; Goss, J R et al. (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-79
Jiang, Canping; Ataai, Mohammad; Ozuer, Ali et al. (2006) Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng 95:48-57
Nakano, Kenji; Asano, Ryutaro; Tsumoto, Kouhei et al. (2005) Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 11:617-26
Moriuchi, Shusuke; Glorioso, Joseph C; Maruno, Motohiko et al. (2005) Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther 12:487-96
Sasaki, Katsumi; Chancellor, Michael B; Goins, William F et al. (2004) Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 53:2723-30
Niranjan, Ajay; Wolfe, Darren; Tamura, Masakazu et al. (2003) Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 8:530-42
Burton, Edward A; Hong, Chang-Sook; Glorioso, Joseph C (2003) The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells. J Virol 77:3516-30
Moriuchi, S; Wolfe, D; Tamura, M et al. (2002) Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 9:584-91

Showing the most recent 10 out of 46 publications